PT  - JOURNAL ARTICLE
AU  - Campos, Rafael K.
AU  - Jin, Jing
AU  - Rafael, Grace H.
AU  - Zhao, Mervin
AU  - Liao, Lei
AU  - Simmons, Graham
AU  - Chu, Steven
AU  - Weaver, Scott C
AU  - Chiu, Wah
AU  - Cui, Yi
TI  - Decontamination of SARS-CoV-2 and other RNA viruses from N95 level meltblown polypropylene fabric using heat under different humidities
AID  - 10.1101/2020.08.10.20171728
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.10.20171728
4099  - http://medrxiv.org/content/early/2020/08/14/2020.08.10.20171728.short
4100  - http://medrxiv.org/content/early/2020/08/14/2020.08.10.20171728.full
AB  - In March of 2020, the World Health Organization declared a pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic led to a shortage of N95-grade filtering facepiece respirators (FFRs), especially for protection of healthcare professionals against airborne transmission of SARS-CoV-2. We and others have previously reported promising decontamination methods that may be applied to the recycling and reuse of FFRs. In this study we tested disinfection of three viruses including SARS-CoV-2, dried on a piece of meltblown fabric, the principal component responsible for filtering of fine particles in N95-level FFRs, under a range of temperatures (60-95°C) at ambient or 100% relative humidity (RH) in conjunction with filtration efficiency testing. We found that heat treatments of 75°C for 30 min or 85°C for 20 min at 100% RH resulted in efficient decontamination from the fabric of SARS-CoV-2, human coronavirus NL63 (HCoV-NL63), and another enveloped RNA virus, chikungunya virus vaccine strain 181 (CHIKV-181), without lowering the meltblown fabric’s filtration efficiency.Competing Interest StatementThe authors declare the following competing financial interest(s): Professors Steven Chu and Yi Cui are founders and shareholders of the company 4C Air, Inc. They are inventors on patent PCT /US2015/065608.Funding StatementThis research was funded by DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act (to W.C.); NIH grant R24 AI120942 to SCWAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COVID-19 virus testing was done according to Biosafety level 3 approved procedures.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data would be available upon request.